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Abstract  
AIM: Prostate cancer (PCa) is the second most common cancers in men worldwide. Its incidence can be 
influenced by several risk factors including genetic susceptibility. Therefore the search for the expression of a 
certain gene (ERG) and its rearrangement could give us clues for proper identification of PCa. And the study of 
ERG expression and its comparison to FISH in Egyptian patients can show whether ERG immunophenotype 
could be used instead of FISH, as it is cheaper.  
MATERIALS AND METHODS: This study was performed on 85 cases of PCa, showing 30 cases with HGPIN 
and 30 cases of prostatic hyperplasia. All were immunohistochemistry stained using ERG monoclonal rabbit 
antihuman antibody was used (clone: EP111). FISH analysis was performed in 38 biopsies of PCa cases to 
detect TMRPSS2-ERG rearrangement using the FISH ZytoLight TriCheck Probe (SPEC TMRPSS2-ERG).  
RESULTS: ERG expression was found in 26% of PCa cases and 20% of HGPIN cases. FISH analysis showed 
fusion of 21 cases of PCa (out of 22 cases showing ERG immunoexpression).  
CONCLUSION: Our findings emphasise that only malignant and pre-malignant cells and not benign cells from the 
prostate stain positive. ERG expression may offer a simpler, accurate and less costly alternative for evaluation of 
ERG fusion status in PCa.
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Prostatic carcinoma (PCa) is a heterogeneous 
disease process with a varied spectrum of light 
microscopic morphologic as well as biological features 
[1-2]. Identification of prostate malignant acini can 
sometimes present a diagnostic challenge for 
pathologists since PCa can mimic benign prostate 
glands [3] and the architectural or cytologic clues for 
the diagnosis of carcinoma may not always be seen in 
small foci of suspicious glands. Histopathological 
diagnosis of PCa can be established by transrectal 
ultrasound-guided (TRUS) biopsy [4] after an 
abnormal finding on digital rectal examination or 
finding an augmentation in prostate-specific antigen 
(PSA) level [5].
 
Prostatic intraepithelial neoplasia (PIN) 
consists of pre-existing prostatic ducts and acini lined 
by cytologically atypical cells. HGPIN is considered 
the precancerous lesion of PCa [6, 7]. There is a 
strong association between HGPIN and PCa. The 
incidence of HGPIN in radical prostatectomy 
specimens for PCa is remarkably high, approximately 
85–100% of specimens [6].  
About 4% of contemporary prostate needle 
biopsies contain collections of small acini that are 
suspicious for cancer and are reported as atypical 
small acinar proliferation (ASAP) suspicious for but 
not diagnostic of malignancy. Prostate cancer has 
been identified in subsequent biopsies in the majority 
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of cases of ASAP, indicating that this finding is a 
significant predictor of cancer [8]. Histopathological 
diagnosis of small focus carcinomas in prostatic 
needle biopsies is often assisted by IHC [9].  
One of the earliest methods of detection of 
this cancer is PSA, which has been used to screen 
since the late 1980s [10]. The early disease diagnosis 
in the Western world is due to the improvement in and 
widespread availability of the measurement of PSA, 
including PSA density, PSA volume and adjusted age-
specific PSA ranges [5]. The free to total (f/t) PSA 
ratio was shown, and this ratio is usually lower in 
patients with PCa than in those with BPH [11]. PCa 
patients with higher Gleason score correlated with 
increased total PSA and decreased free PSA [12].  
ERG (v-ets erythroblastosis virus E26 
oncogene homolog [avian], chromosome 21q22.3) is 
only seen in prostate cancer. It was first reported as 
an overexpression of the oncogene ERG at the 
transcript level in 50% of clinically localised and 
metastatic PCa samples [13]. Numerous studies 
showed that the basis for this overexpression was a 
result of ERG fusion with the promoter region of the 
androgen-induced TMRPSS2-ERG gene, the most 
common variant [14-17] HGPIN showing TMRPSS2-
ERG fusion is associated with co-existing TMPRSS2-
ERG PCa. The detection of isolated TMRPSS2-ERG 
fusion in HGPIN would improve the positive 
prognostic value of finding TMRPSS2-ERGfusion PCa 
in subsequent biopsies [18].  
ERG's oncogenic potential is known because 
of its involvement in Ewig's sarcoma and leukaemia 
[17]. Additionally, ERG is a highly specific endothelial 
marker. It is expressed in small-caliber vessels 
adjacent to PCa using IHC. Hence, it can be used as 
an internal staining control, regardless 
of ERG rearrangement status in cancer [20].  
The aim of the study was to determine the 
frequency of ERG expression in PCa of Egyptian 
patients and in HGPIN lesions juxtaposed to positively 
expressed PCa cases as well as to assess the 
concordance between ERG immunoexpression and 
TMRPSS2-ERG fusion status. 
 
 
Patients and Methods 
 
The present study was conducted on 115 
prostatic cases including 85 patients with PCa, 30 of 
them containing PIN in the adjacent area of the 
tumour and 30 patients diagnosed with prostatic 
hyperplasia. Ten biopsies from patients with 
hemangioma served as a control group: they were five 
males and five females. According to the procedure, 
1) there were 28 cases of TRUS cores, each case 
consisting of 6 tissue core samples, in total = 28 
cases x 6 cores = 168 cores. 
 
We chose the cases of most presentable 
areas and cores were representing a composite 
score, 2) 24 TURP, eight blocks from each case or 24 
x 8 = 192 blocks. We chose blocks containing 
tumours, 3) 33 prostatectomies: we processed 20 
blocks from both lobes = 33x20 = 660 blocks, and we 
chose blocks showing most tumour areas 
representing a composite score. Total 
blocks=162+192+660=1114 blocks, also 30 TRUS 
cases with benign prostatic hyperplasia, 30x6 
cores=180 block. We reconstructed 15 tissue 
microarrays.
 
 
Histopathological study 
Sections were cut from the paraffin block on 
the microtome, 4-micron thickness, and were stained 
with Haematoxylin and Eosin for histopathological 
diagnosis. Scoring was assessed for pathological 
evaluation of cases using Gleason scoring system. 
The PCa cases were sorted into three groups 
according to the current grading criteria of the ISUP 
2014 modified GS (ISUP-GS) [23]: Group 1: GS≤ 6 
(including Grade group 1) included 34 cases, Group 2: 
GS= 7 (including Grade Group 2 & 3) included 25 
cases, and Group 3: GS ≥ 8 (including Grade group 
4&5) included 26 cases.  
 
Immunohistochemical (IHC) technique 
ERG expression was evaluated using a 
commercial rabbit anti-ERG monoclonal antibody 
(cloneEP111; Dako, Denmark A/S). Deparaffinization, 
hydration of the slides, and blocking with pre-antibody 
solution (20 min) where performed in Dako PT Link 
(Code PT100/PT101). Then, a protocol template was 
created. The staining steps and incubation times were 
pre-programmed into the Autostainer Link software 
(Dako Autostainer). These were diluting anti-ERG 
primary antibody (1:50 for 20 min at room temp); 
applying Poly-HRP anti-rabbit IgG (20 min); applying 
DAB (20 min, Sigma Fast DAB tablets, Sigma-Aldrich, 
St. Louis MO); counter staining with EnVision FLEX 
hematoxylin (5 min); and dehydration, clearing, 
mounting, and covering. 
 
Interpretation of immunostaining 
ERG expression is normally observed in 
lymphocytes and endothelium. These cells were used 
as positive internal controls for the ERG staining but 
were not included in the evaluation of ERG fusion 
status, and only nuclear staining was considered to be 
positive. 
The prostatic sections were examined using a 
Zeiss light microscope (Oberkochen, Germany). The 
number of positively stained cells with the highest 
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expression recorded within ten successive fields 
(x400) was counted per section. 
 
Each case was independently assessed by 
two pathologists (HO and KH) using an H-score 
system obtained by multiplying the intensity of the 
stain (0: no staining; 1: weak staining; 2: moderate 
staining; 3: intense staining) by the percentage (0–
100) of the cell showing that staining intensity (H-
score range 0–300). Any nuclear staining positivity (H-
score >0) was considered as indicative of ERG 
expression [22].  
 
Fluorescence in situ hybridization (FISH) 
technique  
The formation of TMRPSS2-ERG fusions 
leads to disruption of the ERG gene locus. Of the 115 
prostatic tissue specimens, 38 specimens were tested 
with the FISH approach including different Gleason 
scores using a previously described triple-color FISH 
assay (Zytolight SPEC TMPRSS2/ERG Tricheck 
probe), that detects the hybridization signals of the 
labelled ERG gene (21q22.2) which appear green and 
orange, whereas the hybridization signals of the 
labelled TMPRSS2 gene (21q22.3) appear blue [23].  
Sections were heated for 10 min at 70°C, 
pretreated by dewaxing and proteolysis. Preparation 
of slides was carried out according to manual. 
TMPRSS2/ERG probe was added, and slides were 
denatured for 10 min at 75°C. Then slides were 
transferred to a humidity chamber and hybridised at 
37°C overnight. Cell nuclei were stained with 
DAPI/Dura Tech-Solution.
 
 
Interpretation of FISH 
Evaluation of the ERG rearrangement is 
carried out by fluorescence microscopy (Olympus 
X51) [using four filters red (FITC), green, blue and 
DAPI] using a × 100 oil immersion objective lens. The 
microscope is attached to high-resolution video 
camera (Jale) and monitor. We captured and 
interpreted photos using hardware (Cytovision 2.3, 
USA). In nuclei without TMRPSS2-ERG 
rearrangements, two green/orange fusion signals and 
two blue signals appeared. An ERG translocation 
without the involvement of TMPRSS2 was indicated 
by the split of one green/orange fusion signal, 
resulting in a separated green signal, near one blue 
signal, and a separated orange signal. On 21q22.13-
q22.3 locus affected by a 21q22.2 deletion resulting in 
the TMPRSS2-ERG, fusion is indicated by one 
separate orange signal co-localizing with one blue 
signal and the loss of one green signal. 
 
 
Statistical analyses 
SPSS software version 18 was used for data 
management and analysis. We did median and 
interquartile range and compared the medians using 
Mann-Whitney U-test. Qualitative data were presented 
as frequencies and percentages. Tests were 
considered statistically significant when P< 0.05. 
 
 
Results 
 
ERG protein expression was analysed by IHC 
in 115 patients who underwent TRUS, TURP, RP, 
open prostatectomy and radical cystoprostatectomy at 
Theodor Bilharz Research Institute in 2014 and 2015. 
85 cases were histopathologically diagnosed as PCa, 
30 cases of HGPIN and ERG positivity was correlated 
to age, PSA, and histological parameters. Patients' 
mean age was 71 years (range 50–88), GS in PCa 
cases was Group 1<7 in 34 (40.1%) including Grade 
group 1, Group 2 = 7 in 25 (29.4%) including Grade 
Group 2 and 3, and Group 3>7 in 26 (30.5%) cases. It 
was expanded by additional FISH analyses of 40 
cases; 38 diagnosed as PCa and two benign cases.
 
 
ERG expression by IHC 
The mean age of ERG positive cases is 67 
years, which is slightly lower than the ERG negative 
cases that are 73 years old with no statistical 
significance. Median total PSA (tPSA) shows a higher 
level in Group 2 & 3 (PCa with GS>7) than Group 1 
(PCa with GS<7) with no statistical significance (Table 
1).  
Table 1: PSA in correlation to different Grade Groups  
 Median P-value Interquartile Range /Median 
Free PSA: 
Group 1 
Group 2 
Group 3 
 
14.28 
10 
20 
 
16.75  (1-64) 
14  (0.8-800) 
31.03  (0.8-500) 
Total PSA: 
Group 1 
Group 2 
Group 3 
 
35 
60 
101 
 
75.88 (5-300) 
123 (4.5-5000) 
216.75 (4-2700) 
PSA ratio 
Group 1 
Group 2 
Group 3 
 
0.25 
0.27 
0.25 
 
0.10 (0.4-0.98) 
0.45 (0.2-0.9) 
0.24 (0.4-0.95) 
Group 1: GS≤ 6 (including Grade group 1) included 34 cases; Group 2: GS= 7 (including 
Grade Group 2&3) included 25 cases; Group 3: GS ≥ 8 (including Grade group 4&5) 
included 26 cases; Using Mann-Whiteny U-test, we found no statistical difference between 
different groups. 
 
Interquartile Range /Median tPSA in ERG 
positive cases was 126.95 (16-300), and ERG 
negative cases were 00.00 (Table 2). 
 
Table 2: Total PSA in correlation to ERG expression by H 
Score
 
ERG expression Total PSA No. of cases Interquartile Range 
/Median 
ERG + ≤ 10 2 00.00 
126.95 (16-300) >10 20 
ERG - ≤ 10 6 00.00 
00.00 > 10 55 
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ERG overexpression was found in 22 (26.0%) 
out of the 85 PCa cases; 2 cases show mild intensity, 
6 cases show moderate intensity, and 14 cases show 
severe intensity. GS groups were sorted into low 
(GS<7), intermediate (GS =7) and high (GS>7), 
revealing a higher prevalence with the higher intensity 
of GS = 7 tumours (50%) in the ERG + group. ERG 
was positive in 6 of 34 specimens (17.6%) with GS<7, 
in 11 of 25 specimens (44%) with GS=7, and in 5 of 
26 specimens (19.2%) with GS>7.
 
 
Figure 1: (A) A case of prostatic carcinoma with Gleason score 3+3 
showing malignant glands infiltrating in-between hyperplastic acini 
(Hx&E) (X10). (B) High grade PIN (Hx&E) (x20). (C) A case of 
prostatic adenocarcinoma showing separated glands lined with 
single epithelial layer, with Gleason score 3+3, radical 
prostatectomy (Hx&E) (x10). (D) A case of prostatic 
adenocarcinoma with Gleason score 3+4, showing separated and 
fused glands (Hx&E) (X40). (E) A case of prostatic adenocarcinoma 
with Gleason score 4+3, TURP (Hx&E) (X10) Fig (F): A case of 
prostatic adenocarcinoma with Gleason score 4+4, TURP (Hx&E) 
(40 HPF) 
 
All benign prostatic hyperplasia cases are 
negative for ERG expression while ERG 
immunoexpression was found in 6 (20%) out of the 30 
HGPIN cases present in the same specimen with 
ERG + PCa cases. HGPIN showed six positive cases; 
5 cases (83.3%) with mild intensity and 1 case 
(16.7%) with moderate intensity of ERG expressed 
HGPIN cases (Figs. 1 & 2).  
Table 3: H score in correlation to different Grade Groups  
       ERG H-SCORE 
Grading Groups  Interquartile Range/Median 
Group 1 (n=34 ) 
Group 2 (n=25 ) 
Group 3 (n=26 ) 
 124.4  (16-300) 
138.4 (52-300) 
207.9(14.4-300) 
Group 1: GS≤ 6 (including Grade group 1) included 34 cases; Group 2: GS= 7 (including 
Grade Group 2&3) included 25 cases; Group 3: GS ≥ 8 (including Grade group 4&5) 
included 26 cases; Using Mann-Whitney U-test, we found no statistical difference between 
different groups. 
 
Figure 2: Prostatic sections stained with ERG 
immunohistochemistry, x200 &400, (A&B) HGPIN with positive 
nuclear staining for ERG, (C&D) PCs, Gleason score 3+3 with mild-
moderate staining for ERG, (E&F) PCs, Gleason score 3+4 with 
moderate – marked staining for ERG, (G) PCs, Gleason score 4+4 
with moderate staining for ERG, (H) PCs, Gleason score 4+5 with 
marked staining for ERG. 
 
H score was increased in group 2 compared 
to group 1 with no statistical significance (Table 3). 
FISH procedure was conducted on 38 cases 
diagnosed as prostatic carcinoma. FISH analysis 
showed TMPRSS2-ERG fusion of 21 cases specimen 
selected of PCa (out of 22 cases that showed ERG 
immunoexpression).  
The gene fusion occurs as a result of either a 
chromosomal translocation or an interstitial deletion, 
where 13 cases show interstitial deletion, and 8 cases 
show chromosomal translocation. Therefore about 
61.9% of cases show deletion and 38.1% show 
translocation (Table 4; Fig. 3). 
Table 4: H score positive IHC cases in correlation to FISH positive 
cases 
 
ERG by IHC 
TMRPSS2- ERG  FISH 
Number of negative         Number of positive  
cases                                   cases 
 
Total 
Negative  
Positive 
Total 
16 
1 
         0 
         21 
16 
22 
38 
ERG overexpression was found in 22 (26.0%) out of 85 PCa cases. TMPRSS2-ERG 
fusion in the specimen selected, 21 cases of the prostatic carcinoma (out of 38 cases) 
show fusion. The gene fusion occurs as a result of either a chromosomal translocation or 
an interstitial deletion, where 13 cases show interstitial deletion, and 8 cases show 
chromosomal translocation. Therefore about 61.9% of cases show deletion and 38.1% 
show translocation.
 
 
B 
C D 
E F 
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We found a strong association between ERG 
immunohistochemical overexpression and TMRPSS2-
ERG rearrangement detected by FISH with 95.5% 
concordance, 100% sensitivity and 94.4% specificity. 
A)
 
B)
 
C) 
 
Figure 3: (A) case of prostatic adenocarcinoma, Gleason score 3+3, 
showing malignant cells with normal expression of  TMRPSS2-ERG 
as merged picture or triple Bandpass filter set (orange, green and 
blue) of SPEC TMRPSS2-ERG TriCheck Probe (FISH, 
magnification × 1000), (B) case of prostatic adenocarcinoma, 
Gleason score 4+4, showing rearranged SPEC TMRPSS2-ERG as 
fusion associated deletion in malignant cells with merged picture or 
triple Bandpass filter set (fused orange and blue, missing green) 
(arrows) (FISH, SPEC TMRPSS2-ERG TriCheck Probe, 
magnification × 1000), (C) case of prostatic adenocarcinoma, 
Gleason score 5+4, showing rearranged SPEC ERG translocation 
not affecting TMPRSS2 in malignant cells with merged picture or 
triple Bandpass filter set ( fused orange and blue, presence of 
green but away) (arrows) (FISH, SPEC TMRPSS2-ERG TriCheck 
Probe, magnification × 1000) 
 
 
 
Discussion 
 
Globally, prostate cancer is reported to be the 
sixth most common type of cancer, and the second 
most common in men, especially in Europe, North 
America, and parts of Africa [24-25]. Studies are 
underway to evaluate new tests for PCa that could 
distinguish more aggressive cancers from those less 
likely to be lethal, to identify men at higher risk of 
developing prostate cancer, and to enable more 
efficient use of PSA testing [26]. Diagnosis, treatment 
and recommendations of PCa are based on biopsy 
assessments. Hence, to affect therapeutic decision 
making, a biomarker must be proved in biopsies [23]. 
In this study, no association between the 
immunoexpression of ERG and the clinical 
parameters including age, and PSA level was found 
(no statistical significance). This is in agreement with 
the study by Rubio-Briones et al. which showed no 
association of ERG status and preoperative PSA [27]. 
On the other hand, a previous PSA screening study 
reported a higher frequency of ERG+ cancer in low 
PSA patients, however, ‘low PSA' was defined as ≤10 
ng /ml[28]. However, two potential limitations in our 
current study are the small sample size and the 
inability to separate age and PSA entirely. Age-
adjusted PSA cut points ensure that a young man with 
a lower PSA is more likely to get a biopsy than an 
older man with the same PSA level. 
Data presented in this study demonstrated 
that ERG was overexpressed in 26% of the PCa 
group whereas most of the studies that have been 
done in Western countries demonstrated that ERG 
gene is overexpressed in approximately 50% in 
patients with PCa [28-31]. However, our results are 
higher than those for Asian patients. For example, 
Chinese prostate cancer patients showed ERG 
overexpression in 14.9% only [37]. Japan and Korea 
also show similar low frequency [32-34].  
This study showed ERG expression in 20% of 
the HGPIN cases (HGPIN in association with PCa in 
the same cases). This is in agreement with other 
studies demonstrating that ERG was expressed in 
27% of HGPIN and that ERG-positive HGPIN is 
strongly associated with positive ERG expression PCa 
in the specimen [35-36]; this indicates that ERG 
fusions appear early in the development of the 
disease.  
Yu and his co-workers found that TMPRSS2-
ERG plays a central role as a "malignant regulatory 
switch" that shuts down androgen signalling inhibiting 
normal prostate differentiation [37]. Our study showed 
that ERG is expressed in the PCa cases with Gleason 
score (GS) equal to 6 or higher. This is in agreement 
with other studies that support the role for TMRPSS2-
ERG fusion in the initiation of carcinogenesis, as it is 
found in early lesions and typically homogenously 
maintained within high-grade tumours [38-41]. 
Previous papers have reported an association with 
low-grade prostate tumours [42-44]; whereas other 
studies support an association with high-grade ones 
[45]. 
 
ERG expression showed no correlation to 
different GS groups with any statistical significance. 
Our results, in agreement with many studies, did not 
find any association between the rearrangement and 
Gleason grade [47-51]. Conversely, previous studies 
showed that higher GS were associated with an 
increased frequency of TMRPSS2-ERG fusion event; 
ERG expression is inversely related to GS [51-53]. A 
recent study reported that the expression levels of 
TMRPSS2-ERG and ERG mRNA are related to more 
aggressive tumours [54]. However, there is 
controversy about the role of TMRPSS2-ERG in the 
development and progression of PCa [51-55].  
The standard assessment for TMRPSS2-ERG 
is FISH [23]. In our research study, we have 
compared the result of ERG immunoexpression with 
TMRPSS2-ERG fusion status that revealed high 
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sensitivity (100%) and high specificity (94.4%) with a 
concordance of 95.5%. This is in agreement with Berg 
and his colleagues’ study that showed a sensitivity of 
100% and a specificity of 95.5% for an ERG 
rearrangement of 100%. This is in agreement with 
Jiang and his colleagues’ study that showed 
correlation with 100% sensitivity and 88.9% specificity 
[56]. Furthermore, many former studies have 
displayed high sensitivities (95.7%–99.1%) and 
specificities (92.3–99.4%) [57-58]. Consequently, our 
research applied ERG protein overexpression to 
determine the presence or absence of TMRPSS2-
ERG rearrangement. We established that detection of 
ERG expression by IHC technique could be used as a 
surrogate marker for ERG rearrangement, in 
agreement with Svensson et al. and Berg and his co-
workers [23, 57].  
In conclusion, the prevalence of ERG protein 
expression is 26% in Egyptian patients with PCa. 
ERG immunoexpression was present in 20% of 
HGPIN lesions exclusively when juxtaposed to fusion 
positive PCa, implying that this is an early event in the 
process of PCa formation. The standard 
immunohistochemistry has high accuracy for defining 
ERG fusion status in men with PCa. Consequently, 
ERG expression may offer a simpler, accurate and 
less costly alternative for evaluation of ERG fusion 
status in PCa. The association between ERG 
expression and prostate cancer based on the 
Egyptian population should be further investigated.
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